ARIX BIOSCIENCE PLC — M&A Activity 2017

Mar 2, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2940Y

Arix Bioscience Plc

02 March 2017

Arix Bioscience plc signs strategic agreement with Takeda

LONDON, 2 MARCH 2017: Arix Bioscience plc (LSE:ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announces a strategic agreement with Takeda Ventures, Inc. ("Takeda").

The agreement will maximise the complementary skills and experience of both Arix and Takeda across important therapeutic areas.

The relationship brings together the unique combination of entrepreneurial business building, investing and industry operating skills at Arix with the deep industry experience of Takeda, to the mutual benefit of both businesses.

Arix will provide Takeda with access to deal flow and a specialist team across its activities to create and incubate companies in partnership with Takeda, guided by a joint advisory committee comprising five appointees from both companies. Takeda has identified the fields of oncology and gastrointestinology as areas of particular interest.

Takeda invested in Arix's recent £100 million (gross) initial public offering on the Main Market of the London Stock Exchange.

Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: "Arix and Takeda have a common goal in sourcing and building the best innovation in healthcare and life sciences.

"Through this agreement with Takeda we can draw upon a wealth of experience in identifying, creating and growing companies to develop innovative new therapies and  further develop existing and new group businesses, accelerating their growth and creating value for our investors."

Michael Martin, Global Head of Takeda Ventures, Inc., added: "Arix has an experienced team whose specialist knowledge, capability and network has the potential to identify and grow innovative companies of the future. Within our focus areas of oncology and GI, and more broadly, we are confident that this agreement provides an opportunity to remain at the forefront of life science developments."

ENDS

For more information, please contact:

Arix Bioscience PLC

Joe Anderson, CEO

+44 (0) 20 7290 1052

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRUAOARBSAORUR